Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.
Fiche publication
Date publication
décembre 2017
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe, Dr GEOFFROIS Lionnel
Tous les auteurs :
Loriot Y, Pagliaro L, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Laplanche A, Le Teuff G, Culine S, Fizazi K
Lien Pubmed
Résumé
The GETUG 13 phase III trial tested personalised chemotherapy based on tumour marker decline in patients with poor-prognosis germ-cell tumour (GCT) and demonstrated that a dose-dense regimen improves progression-free survival in patients with an unfavourable decline. We investigated the pattern of relapse for patients included in GETUG 13.
Mots clés
Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Brain Neoplasms, diagnostic imaging, Clinical Trials, Phase III as Topic, Disease Progression, Disease-Free Survival, France, Humans, Kaplan-Meier Estimate, Magnetic Resonance Imaging, Male, Multicenter Studies as Topic, Neoplasms, Germ Cell and Embryonal, diagnostic imaging, Proportional Hazards Models, Retrospective Studies, Risk Factors, Testicular Neoplasms, diagnostic imaging, Time Factors, Tomography, X-Ray Computed, Treatment Outcome, United States
Référence
Eur. J. Cancer. 2017 12;87:140-146